Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, according to a global phase 3 trial.
The LumiSystem is a detection tool that uses fluorescence imaging technology during lumpectomy, offering a more complete resection vs other detection systems that evaluate tissue after surgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback